As shown in Figure 2B, similar findings were observed if patients with insufficient VEGF-D samples were excluded: the percent change in the kidney tumor size (sum LD) at 24 months for the OFF SIROLIMUS AFTER 12 MONTHS group was 1.9% (n = 12), but was −23.8% in the ON SIROLIMUS AFTER 12 MONTHS group (n = 6); this difference was significant (p = 0.022, Mann-Whitney test). This evidence concerns the gene VEGFD and kidney neoplasm.